Tuberculosis (TB) remains the leading bacterial cause of death worldwide, complicated by long treatment regimens and the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains. Our lab is developing several new approaches to combat TB. We are evaluating oxicam analogues as novel antibiotic candidates and optimising nitrofuran isooxazolines and oxazolidinones as next-generation TB drugs, with activity against non-tubercular mycobacteria as well.
Another major project involves metabolite mimics that target a key metabolic enzyme, potentiating existing TB drugs by increasing their effectiveness. These small molecules are inexpensive to produce, drug-like, and non-toxic to human cells, making them strong candidates for rapid clinical translation as antibiotic adjuvants.
In collaboration with the University of Surrey and the UK Health Security Agency, we are carrying out preclinical assessments to demonstrate pharmacological suitability and therapeutic potential. Funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, our work aims to extend the lifespan of existing drugs, improve treatment outcomes, and contribute to global efforts to control TB and antimicrobial resistance.